Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134748552> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3134748552 endingPage "258" @default.
- W3134748552 startingPage "257" @default.
- W3134748552 abstract "Aims & Objectives: To evaluate the current prescribing, dosing and monitoring of Vancomycin in critically ill children reviewing effectiveness of current guidelines in reaching therapeutic trough target levels in the initial 48 hours of treatment. Methods: A single center retrospective chart review of children aged 1 month to 16 years admitted to the Pediatric Intensive Care Unit (PICU) and prescribed vancomycin therapy for ≥ 24 hours over 2 years. Results: 76% (46/60) of the participants were aged <5 years. Pneumonia was the leading primary admission diagnosis with infections of respiratory origin comprising 73.33%(44/60) of all cases requiring Vancomycin. Laboratory confirmed Methicillin Resistant Staphylococcus Aureus (MRSA) cases was 28% (17/60) with 70.58% (12/17) of these being children of Aboriginal or Torres Strait Islander (ATSI) ethnicity. The median serum Vancomycin plasma concentration (SVPC) fell below the therapeutic trough target of 15-20mg/ml for all dosing regimens. 8.33% (5/60) did not have Vancomycin levels taken and 54.54% (30/55) never reached the therapeutic targets. 20% (11/55) reached therapeutic targets in <48 hours and 23.6% (13/55) reached therapeutic targets in >48 hours.Conclusions: Current dosing regimens demonstrate efficacy in reaching therapeutic levels in initial 48 hours of treatment in 20% of cases and over half of the children prescribed Vancomycin never achieve the current therapeutic trough ranges currently specified. Further prospective investigation is needed with a view to use of Area under curve (AUC) and minimum inhibitory concentration (MIC) as markers of efficacy in our local population to determine if customised pharmacokinetic (PK) dosing models offer a better alternative." @default.
- W3134748552 created "2021-03-15" @default.
- W3134748552 creator A5000272819 @default.
- W3134748552 creator A5041553703 @default.
- W3134748552 creator A5081709587 @default.
- W3134748552 date "2021-03-01" @default.
- W3134748552 modified "2023-09-27" @default.
- W3134748552 title "P0512 / #1237: OPTIMAL SERUM VANCOMYCIN MONITORING IN CRITICALLY ILL CHILDREN WITH COMPLEX INFECTIONS: ARE WE REACHING RECOMMENDED THERAPEUTIC TARGETS?" @default.
- W3134748552 doi "https://doi.org/10.1097/01.pcc.0000740388.66444.a3" @default.
- W3134748552 hasPublicationYear "2021" @default.
- W3134748552 type Work @default.
- W3134748552 sameAs 3134748552 @default.
- W3134748552 citedByCount "0" @default.
- W3134748552 crossrefType "journal-article" @default.
- W3134748552 hasAuthorship W3134748552A5000272819 @default.
- W3134748552 hasAuthorship W3134748552A5041553703 @default.
- W3134748552 hasAuthorship W3134748552A5081709587 @default.
- W3134748552 hasBestOaLocation W31347485521 @default.
- W3134748552 hasConcept C112705442 @default.
- W3134748552 hasConcept C126322002 @default.
- W3134748552 hasConcept C177713679 @default.
- W3134748552 hasConcept C187212893 @default.
- W3134748552 hasConcept C2776376669 @default.
- W3134748552 hasConcept C2777288759 @default.
- W3134748552 hasConcept C2777914695 @default.
- W3134748552 hasConcept C2778980435 @default.
- W3134748552 hasConcept C2779489039 @default.
- W3134748552 hasConcept C2780272996 @default.
- W3134748552 hasConcept C2908647359 @default.
- W3134748552 hasConcept C2909675724 @default.
- W3134748552 hasConcept C2911091166 @default.
- W3134748552 hasConcept C31785415 @default.
- W3134748552 hasConcept C523546767 @default.
- W3134748552 hasConcept C54355233 @default.
- W3134748552 hasConcept C71924100 @default.
- W3134748552 hasConcept C86803240 @default.
- W3134748552 hasConcept C99454951 @default.
- W3134748552 hasConceptScore W3134748552C112705442 @default.
- W3134748552 hasConceptScore W3134748552C126322002 @default.
- W3134748552 hasConceptScore W3134748552C177713679 @default.
- W3134748552 hasConceptScore W3134748552C187212893 @default.
- W3134748552 hasConceptScore W3134748552C2776376669 @default.
- W3134748552 hasConceptScore W3134748552C2777288759 @default.
- W3134748552 hasConceptScore W3134748552C2777914695 @default.
- W3134748552 hasConceptScore W3134748552C2778980435 @default.
- W3134748552 hasConceptScore W3134748552C2779489039 @default.
- W3134748552 hasConceptScore W3134748552C2780272996 @default.
- W3134748552 hasConceptScore W3134748552C2908647359 @default.
- W3134748552 hasConceptScore W3134748552C2909675724 @default.
- W3134748552 hasConceptScore W3134748552C2911091166 @default.
- W3134748552 hasConceptScore W3134748552C31785415 @default.
- W3134748552 hasConceptScore W3134748552C523546767 @default.
- W3134748552 hasConceptScore W3134748552C54355233 @default.
- W3134748552 hasConceptScore W3134748552C71924100 @default.
- W3134748552 hasConceptScore W3134748552C86803240 @default.
- W3134748552 hasConceptScore W3134748552C99454951 @default.
- W3134748552 hasIssue "Supplement 1 3S" @default.
- W3134748552 hasLocation W31347485521 @default.
- W3134748552 hasLocation W31347485522 @default.
- W3134748552 hasOpenAccess W3134748552 @default.
- W3134748552 hasPrimaryLocation W31347485521 @default.
- W3134748552 hasRelatedWork W1831522254 @default.
- W3134748552 hasRelatedWork W2012166348 @default.
- W3134748552 hasRelatedWork W2109792151 @default.
- W3134748552 hasRelatedWork W2112943695 @default.
- W3134748552 hasRelatedWork W2160515228 @default.
- W3134748552 hasRelatedWork W3134748552 @default.
- W3134748552 hasRelatedWork W3186689997 @default.
- W3134748552 hasRelatedWork W4225930705 @default.
- W3134748552 hasRelatedWork W4313729222 @default.
- W3134748552 hasRelatedWork W4381706042 @default.
- W3134748552 hasVolume "22" @default.
- W3134748552 isParatext "false" @default.
- W3134748552 isRetracted "false" @default.
- W3134748552 magId "3134748552" @default.
- W3134748552 workType "article" @default.